The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Tocilizumab has demonstrated optimal efficacy and safety in patients with rheumatoid arthritis (RA) from clinical trials. However, the risk of hepatitis B virus reactivation (HBVr) in these patients remains uncertain because patients with underlying HBV have been excluded in phase III studies.

Methods

Systematical reviews were conducted on PubMed, Embase, and the Cochrane Central Register of Controlled Trials up to 21 February 2023. Random-effects meta-analysis was performed to calculate the pooled incidence of HBV reactivation.

Results

We included 0 clinical trials and 11 observational studies with a total of 25 HBsAg⁺ and 322 HBsAg^-/anti-HBc⁺ RA patients. Among the HBsAg⁺ patients without antiviral prophylaxis,

SUBMITTER: Ko PH 

PROVIDER: S-EPMC10820547 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature